What is the share price of Oxygenta Pharmaceutical Ltd (OXYGENTAPH) today?
The share price of OXYGENTAPH as on 11th September 2026 is ₹55.88. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Oxygenta Pharmaceutical Ltd (OXYGENTAPH) share?
The past returns of Oxygenta Pharmaceutical Ltd (OXYGENTAPH) share are- Past 1 week: -0.04%
- Past 1 month: -4.97%
- Past 3 months: 25.26%
- Past 6 months: 11.49%
- Past 1 year: -21.75%
- Past 3 years: 49.69%
- Past 5 years: 61.27%
What are the peers or stocks similar to Oxygenta Pharmaceutical Ltd (OXYGENTAPH)?
The peers or stocks similar to Oxygenta Pharmaceutical Ltd (OXYGENTAPH) include:What is the market cap of Oxygenta Pharmaceutical Ltd (OXYGENTAPH) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Oxygenta Pharmaceutical Ltd (OXYGENTAPH) is ₹236.14 Cr as of 11th September 2026.What is the 52 week high and low of Oxygenta Pharmaceutical Ltd (OXYGENTAPH) share?
The 52-week high of Oxygenta Pharmaceutical Ltd (OXYGENTAPH) is ₹74.99 and the 52-week low is ₹43.What is the PE and PB ratio of Oxygenta Pharmaceutical Ltd (OXYGENTAPH) stock?
The P/E (price-to-earnings) ratio of Oxygenta Pharmaceutical Ltd (OXYGENTAPH) is -13.44. The P/B (price-to-book) ratio is -5.53.Which sector does Oxygenta Pharmaceutical Ltd (OXYGENTAPH) belong to?
Oxygenta Pharmaceutical Ltd (OXYGENTAPH) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Oxygenta Pharmaceutical Ltd (OXYGENTAPH) shares?
You can directly buy Oxygenta Pharmaceutical Ltd (OXYGENTAPH) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Oxygenta Pharmaceutical Ltd
OXYGENTAPH Share Price
BSE₹55.883.87% (+2.08)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
OXYGENTAPH Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
OXYGENTAPH Performance & Key Metrics
OXYGENTAPH Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| -17.38 | -5.53 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 46.35 | 5.84 | 0.49% |
OXYGENTAPH Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
OXYGENTAPH Company Profile
Oxygenta Pharmaceutical Limited manufactures bulk drugs and active pharmaceutical ingredients (API), including a range of pharmaceutical preparations and organic fine chemicals.
SUNPHARMA
PE Ratio
39.76
39.76
1Y Return
14.31%
14.31%
Buy Reco %
93.55
93.55
TORNTPHARM
PE Ratio
86.09
86.09
1Y Return
38.56%
38.56%
Buy Reco %
81.48
81.48
CIPLA
PE Ratio
29.83
29.83
1Y Return
12.48%
12.48%
Buy Reco %
62.86
62.86
ZYDUSLIFE
PE Ratio
22.17
22.17
1Y Return
7.23%
7.23%
Buy Reco %
57.69
57.69
LUPIN
PE Ratio
18.88
18.88
1Y Return
5.38%
5.38%
Buy Reco %
51.52
51.52
OXYGENTAPH Forecast
OXYGENTAPH Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
OXYGENTAPH
OXYGENTAPH
Income
Balance Sheet
Cash Flow
Quarterly Normal View
OXYGENTAPH Income Statement
OXYGENTAPH Income Statement
Quarterly Normal View
| Quarter | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | jun 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 10.81 | 12.64 | 14.75 | 33.69 | 49.52 | 15.30 | 14.25 | 33.93 | 49.79 | 37.02 | ||||||||||
Operating & Other expenses | 12.17 | 14.40 | 16.18 | 37.56 | 51.42 | 21.98 | 18.88 | 38.01 | 49.50 | 36.45 | ||||||||||
EBITDA | -1.36 | -1.76 | -1.43 | -3.87 | -1.90 | -6.68 | -4.63 | -4.08 | 0.29 | 0.57 | ||||||||||
| Depreciation/Amortization | 0.64 | 0.65 | 0.66 | 0.71 | -0.23 | 0.85 | 0.86 | 0.86 | -0.24 | 0.62 | ||||||||||
| PBIT | -2.00 | -2.41 | -2.09 | -4.58 | -1.67 | -7.53 | -5.49 | -4.94 | 0.53 | -0.05 | ||||||||||
| Interest & Other Items | 0.59 | 0.41 | 0.69 | 0.39 | 2.13 | 0.63 | 0.95 | 1.39 | 1.81 | 2.46 | ||||||||||
| PBT | -2.59 | -2.82 | -2.78 | -4.97 | -3.80 | -8.16 | -6.44 | -6.33 | -1.28 | -2.51 | ||||||||||
| Taxes & Other Items | -10.60 | -1.45 | 0.08 | -1.03 | -1.65 | -2.04 | -1.51 | -1.48 | 0.42 | -0.40 | ||||||||||
| Net Income | 8.01 | -1.37 | -2.86 | -3.94 | -2.15 | -6.12 | -4.93 | -4.85 | -1.70 | -2.11 | ||||||||||
| EPS | 2.55 | -0.39 | -0.81 | 1.07 | -0.60 | -1.65 | -1.33 | -1.32 | -0.45 | -0.57 |
OXYGENTAPH Company Updates
OXYGENTAPH Stock Peers
OXYGENTAPH Past Performance & Peer Comparison
OXYGENTAPH Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Oxygenta Pharmaceutical Ltd | -13.44 | -5.53 | — |
| Sun Pharmaceutical Industries Ltd | 39.76 | 5.44 | 0.84% |
| Torrent Pharmaceuticals Ltd | 86.09 | 10.59 | 0.69% |
| Cipla Ltd | 29.83 | 3.35 | 0.91% |
OXYGENTAPH Stock Price Comparison
Compare OXYGENTAPH with any stock or ETFCompare OXYGENTAPH with any stock or ETF
OXYGENTAPH
OXYGENTAPH Holdings
OXYGENTAPH Shareholdings
OXYGENTAPH Promoter Holdings Trend
OXYGENTAPH Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
OXYGENTAPH Institutional Holdings Trend
OXYGENTAPH Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
OXYGENTAPH Shareholding Pattern
OXYGENTAPH Shareholding Pattern
OXYGENTAPH Shareholding History
OXYGENTAPH Shareholding History
Foreign Institutions
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing OXYGENTAPH stock
smallcases containing OXYGENTAPH stock
Looks like this stock is not in any smallcase yet.
OXYGENTAPH Events
OXYGENTAPH Events
OXYGENTAPH Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
OXYGENTAPH has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
OXYGENTAPH Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
OXYGENTAPH has not given any dividends in last 5 years
OXYGENTAPH Dividends
OXYGENTAPH Dividends
Hmm, looks like data is unavailable here. Please come back after some timeOXYGENTAPH Stock News & Opinions
OXYGENTAPH Stock News & Opinions
Articles & Videos
Corporate
Corporate
Oxygenta Pharmaceutical to convene AGMOxygenta Pharmaceutical announced that the Annual General Meeting(AGM) of the company will be held on 21 August 2026.
1 month agoCapital Market - Live
Earnings
Earnings
Oxygenta Pharmaceutical reports standalone net loss of Rs 2.10 crore in the June 2026 quarterNet Loss of Oxygenta Pharmaceutical reported to Rs 2.10 crore in the quarter ended June 2026 as against net loss of Rs 6.11 crore during the previous quarter ended June 2025. Sales rose 144.55% to Rs 37.00 crore in the quarter ended June 2026 as against Rs 15.13 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales37.0015.13 145 OPM %1.51-45.14 - PBDT-1.88-7.29 74 PBT-2.50-8.14 69 NP-2.10-6.11 66 Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Corporate
Oxygenta Pharmaceutical postpones board meetingOxygenta Pharmaceutical has postponed the meeting of the Board of Directors which was scheduled to be held on 25 July 2026. The meeting will now be held on 27 July 2026.
1 month agoCapital Market - Live
Corporate
Corporate
Oxygenta Pharmaceutical schedules board meetingOxygenta Pharmaceutical will hold a meeting of the Board of Directors of the Company on 25 July 2026.
1 month agoCapital Market - Live
Earnings
Earnings
Oxygenta Pharmaceutical reports standalone net loss of Rs 1.70 crore in the March 2026 quarterNet Loss of Oxygenta Pharmaceutical reported to Rs 1.70 crore in the quarter ended March 2026 as against net loss of Rs 2.15 crore during the previous quarter ended March 2025. Sales rose 0.28% to Rs 49.61 crore in the quarter ended March 2026 as against Rs 49.47 crore during the previous quarter ended March 2025. For the full year,net loss reported to Rs 17.57 crore in the year ended March 2026 as against net loss of Rs 10.30 crore during the previous year ended March 2025. Sales rose 3.37% to Rs 112.98 crore in the year ended March 2026 as against Rs 109.30 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales49.6149.47 0 112.98109.30 3 OPM %0.24-3.40 --13.60-9.15 - PBDT-1.52-3.76 60 -19.86-10.47 -90 PBT-1.28-3.53 64 -22.18-14.08 -58 NP-1.70-2.15 21 -17.57-10.30 -71 Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Corporate
Oxygenta Pharmaceutical announces board meeting dateOxygenta Pharmaceutical will hold a meeting of the Board of Directors of the Company on 23 May 2026.
3 months agoCapital Market - Live
Earnings
Earnings
Oxygenta Pharmaceutical reports standalone net loss of Rs 4.84 crore in the December 2025 quarterNet Loss of Oxygenta Pharmaceutical reported to Rs 4.84 crore in the quarter ended December 2025 as against net loss of Rs 3.93 crore during the previous quarter ended December 2024. Sales rose 2.17% to Rs 33.93 crore in the quarter ended December 2025 as against Rs 33.21 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales33.9333.21 2 OPM %-12.00-13.10 - PBDT-5.46-4.25 -28 PBT-6.32-4.96 -27 NP-4.84-3.93 -23 Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Corporate
Oxygenta Pharmaceutical schedules board meetingOxygenta Pharmaceutical will hold a meeting of the Board of Directors of the Company on 4 February 2026.Powered by Capital Market - Live
7 months agoCapital Market - Live
Earnings
Earnings
Oxygenta Pharmaceutical reports standalone net loss of Rs 4.93 crore in the September 2025 quarterNet Loss of Oxygenta Pharmaceutical reported to Rs 4.93 crore in the quarter ended September 2025 as against net loss of Rs 2.85 crore during the previous quarter ended September 2024. Sales rose 2.07% to Rs 14.30 crore in the quarter ended September 2025 as against Rs 14.01 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales14.3014.01 2 OPM %-31.96-15.49 - PBDT-5.58-2.11 -164 PBT-6.44-2.77 -132 NP-4.93-2.85 -73 Powered by Capital Market - Live
10 months agoCapital Market - Live
Corporate
Corporate
Oxygenta Pharmaceutical to conduct board meetingOxygenta Pharmaceutical will hold a meeting of the Board of Directors of the Company on 7 November 2025.Powered by Capital Market - Live
10 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 15.84%, vs industry avg of 11.79%
Over the last 5 years, market share stayed at 0.02%